Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
500 participants
INTERVENTIONAL
2022-09-14
2026-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers.
Objective:
To learn how well vaccines work in people who have certain types of blood cancers.
Eligibility:
Adults aged 18 years or older who have chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia, or certain non-Hodgkin lymphomas.
Design:
Participants will get one or more vaccines for illnesses such as COVID-19, hepatitis B, and shingles. They can choose which vaccines they receive. They will give a blood sample before they get each vaccine. Some vaccines require a second dose 3-6 weeks later. Participants may give an optional blood sample with the second vaccine dose. About 4 weeks after they finish each vaccine series, they will give another blood sample. They will have 2-3 study visits per vaccine.
Participants may receive a booster dose for some vaccines. The booster dose is optional. They will give another blood sample with the booster dose.
Participants will have pregnancy tests, if needed.
Participants with CLL who receive BTKis may be asked to pause treatment for up to 7 weeks.
Participants may give follow-up blood samples up to 2 times a year for 5 years. These blood samples are optional.
Participation will last for up to 5 years after each vaccine series is received.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma
NCT00193492
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
NCT00010192
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
NCT00133991
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022
Fludarabine and Monoclonal Antibody Therapy in Treating Patients With Untreated B-cell Chronic Lymphocytic Leukemia
NCT00003248
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study aims to determine vaccine titers in B-cell malignancies; specifically, in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), or other non-Hodgkin lymphomas (NHL) \[follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphomas (MZLs) and indolent NHL not otherwise specified (NOS)\], or in Waldenstrom Macroglobulinemia (WM).
Note: Since CLL and SLL are considered the same disease, CLL/SLL will be referred to as CLL hereafter, unless otherwise specified.
Objectives: Primary Objective:
Determine vaccine titers following vaccination in patients with B-cell malignancies who are either receiving targeted therapies or not receiving active treatment
Secondary Objectives:
1. Determine vaccine titers in patients with CLL that are treatment naive, not receiving active treatment, or receiving targeted therapies
2. Determine whether interruption of Bruton tyrosine kinase inhibitor (BTKi) therapy around the time of vaccination improves vaccine titers in patients with CLL
3. Determine vaccine titers in patients with NHL (FL, MCL, MZL, NHL NOS) or WM that are not receiving active treatment, or receiving targeted therapies
Endpoints:
The primary efficacy endpoint will be the serologic titer against each administered vaccine following completion of the vaccine series in each study arm
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Lymphocytic Leukemia Not Receiving Active Treatment
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Chronic Lymphocytic Leukemia Treatment Break for BTKi
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Chronic Lymphocytic Leukemia Treatment Naive
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Chronic Lymphocytic Leukemia Treatment with BTKi
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Follicular Lymphoma
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Follicular Lymphoma Treatment Naive
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Other Non-Hodgkin Lymphoma and Waldenstrom Macroglobulinemia - Treatment with Targeted Therapies
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Participants diagnosed with Chronic Lymphocytic Leukemia (CLL)
Participants may receive one or more of the following vaccine types: Shingrix, Heplisav -B, Fluzone, Afluria, Fluarix, Flucelvax, FluLaval, PREVNAR 13, PNEUMOVAX 23, Pfizer-COVID-19, Moderna-COVID-19 and receive assessment of serologic and cellular response following completion of each vaccine series.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluzone
Annual Influenza Vaccine
Shingrix
Recombinant, adjuvanted Zoster Vaccine (RZV)
Flucelvax
Annual Influenza Vaccine
Afluria
Annual Influenza Vaccine
PREVNAR 13
Pneumococcal Conjugate Vaccine (PCV13)
Heplisav -B
Recombinant, adjuvanted Hepatitis (HepB-CpG)
Pfizer-COVID-19 Vaccine
COVID-19 Vaccine
FluLaval
Annual Influenza Vaccine
Fluarix
Annual Influenza Vaccine
PNEUMOVAX 23
Pneumococcal Polysaccharide Vaccine (PPSV23)
PREVNAR 20
Pneumococcal 20-Valent Conjugate Vaccine (PCV20)
AREXVY, ABRYSVO
Respiratory Syncytial Virus Vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must fulfil one of the following criteria to be enrolled in one study arm per vaccine received:
1. Patients with CLL AND one of the following:
i. Arm 1: Must be treatment naive (no prior cancer directed therapy)
ii. Arm 2: Patients that have received prior cancer directed therapy and are currently not receiving active treatment
iii. Arm 3: Must be receiving treatment with a BTKi. This arm is not available to patients receiving the HEPLISAV-B vaccine
iv. Arm 4: Must be receiving treatment with a BTKi for \>= 6 months prior to vaccination and be willing to hold their treatment for up to 7 weeks around the time of each vaccination. This arm is not available to patients who have had a prior episode of disease flare during periods of drug hold, or for patients with CLL that is actively progressing.
v. Arm 5: Must be receiving treatment with a BCL-2 inhibitor
Or
2. Patients with FL, MCL, MZL, NHL NOS or WM AND one of the following:
i. Arm 1: Must currently not be receiving active treatment (treatment na(SqrRoot) ve or previously treated)
ii. Arm 2: Must be receiving treatment with targeted therapies (e.g. BTKi, BCL-2 inhibitors, PI3K inhibitors, immunomodulatory agents, proteasome inhibitors)
* If prior exposure to Hepatitis-B vaccination, must have documentation of negative serologic response
* Age \>= 18 years
* Able to comprehend the investigational nature of the protocol and provide informed consent
Exclusion Criteria
2. History of severe allergic reaction to vaccines
3. Concomitant inherited immunodeficiency
4. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk.
5. Receive cytotoxic chemotherapy within 2 weeks prior to vaccination
6. Receive intravenous immunoglobulin (IVIG) within 2 months prior to vaccination
7. Receive anti-CD20 and/or anti-CD19 monoclonal antibody therapy within 6 months prior to vaccination
8. Receive cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination
9. History of allogeneic stem cell transplantation
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adrian U Wiestner, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Heart, Lung, and Blood Institute (NHLBI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
000444-H
Identifier Type: -
Identifier Source: secondary_id
10000444
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.